431 results on '"Abiko, Kaoru"'
Search Results
2. Real-world application of comprehensive genomic profiling for gynecological malignancies: a multicenter observational study
3. Structural Insights into SARS-CoV-2 Transmission between Humans and Other Mammals
4. Dynamic host immunity and PD-L1/PD-1 blockade efficacy: developments after “IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer”
5. Tertiary lymphoid structures are associated with favorable survival outcomes in patients with endometrial cancer
6. Visceral-to-subcutaneous fat ratio is a possible prognostic factor for type 1 endometrial cancer
7. Lower systolic blood pressure levels in early pregnancy are associated with a decreased risk of early-onset superimposed preeclampsia in women with chronic hypertension: a multicenter retrospective study
8. Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment
9. Robotic Surgery for Gynecologic Cancer
10. Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer
11. Patients With Hereditary Gastric Cancer Linked to a Family History of Hereditary Breast and Ovarian Cancer (HBOC)
12. Supplementary Figure legend from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma
13. Supplementary Table 3 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma
14. Supplementary Table 7 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma
15. Supplementary Table 8 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma
16. Supplementary Table 6 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma
17. Data from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma
18. Supplementary Figure 2 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma
19. Supplementary Table 9 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma
20. Supplementary Table 4 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma
21. Supplementary Table 5 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma
22. Supplementary Table 1 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma
23. Supplementary Figure 1 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma
24. Supplementary Table 2 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma
25. Clinical features of cases in which mature teratomas of the ovary were misdiagnosed as immature teratomas
26. FSH-producing pituitary neuroendocrine tumor as a cause of ovarian hyperstimulation syndrome
27. Treatment With Antitumor Agents Recommended by Cancer Genome Panel for Uterine Leiomyosarcoma
28. Primary signet ring cell carcinoma of uterine cervix and related disease: two case reports and a review
29. Immunology and Immunotherapy in Ovarian Cancer
30. Immunotherapy for Gynecologic Cancer
31. EP351/#229 Clinical factors relevant to inter-observer reproducibility in pathological diagnosis of immature teratoma of the ovary: a retrospective study of 148 cases
32. EP002/#234 Results of clinical research (PRUM-IBIO study): establishment of prognostic biomarkers for uterine mesenchymal tumors
33. SLFN11 is a BRCA independent biomarker for the response to platinum-based chemotherapy in high-grade serous ovarian cancer and clear cell ovarian carcinoma
34. Exome Sequencing Landscape Analysis in Ovarian Clear Cell Carcinoma Shed Light on Key Chromosomal Regions and Mutation Gene Networks
35. VISTA expressed in tumour cells regulates T cell function
36. A Novel Direct Approach to the Deep Uterine Vein in Laparoscopic Radical Hysterectomy
37. Right-sided Sigmoid Colon Revealed during Laparoscopic Sacrocolpopexy
38. [Communication] Potential Life Prognostic Marker for Mesenchymal Tumor Resembling Uterine Leiomyosarcoma
39. Characteristic of Endometrial Stromal Sarcoma by Algorithm of Potential Biomarkers for Uterine Mesenchymal Tumor
40. Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes
41. Prediction of taxane and platinum sensitivity in ovarian cancer based on gene expression profiles
42. Acquisition of a side population fraction augments malignant phenotype in ovarian cancer
43. [Case Report] Characteristic of Endometrial stromal sarcoma by algorithm of potential biomarkers for uterine mesenchymal tumor
44. [Communication] Histopathological findings of ectopic pregnancy in contraceptive-wearing women
45. Supplementary Data from B7-H3 Suppresses Antitumor Immunity via the CCL2–CCR2–M2 Macrophage Axis and Contributes to Ovarian Cancer Progression
46. Data from B7-H3 Suppresses Antitumor Immunity via the CCL2–CCR2–M2 Macrophage Axis and Contributes to Ovarian Cancer Progression
47. Supplementary Figure 4 from Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells
48. Supplementary Video 1 from PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction
49. Supplementary Figure 3 from Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells
50. Supplementary Table 2 from PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.